CagriSema vs Zepbound: Next-Gen GLP-1 Showdown

CagriSema: 22.7% weight loss in the REDEFINE-2 Phase 3 trial over 68 weeks. Zepbound: 22.5% in the SURMOUNT-1 Phase 3 trial over 72 weeks. The 0.2 percentage-point difference is not clinically meaningful — these drugs are functionally tied on efficacy.

For a 240 lb patient, both produce roughly 54 lbs of weight loss. That's a transformative result from either drug.

Important caveat: This is a cross-trial comparison, not a head-to-head study. Patient populations, trial designs, and durations differed. A direct comparison trial has not been conducted. However, the numbers are close enough that most obesity medicine experts consider them equivalent.

Both drugs represent the ceiling of what current injectable GLP-1 combinations can achieve. The next frontier (retatrutide at 28.7%) adds a third receptor, but it's still in trials.

These drugs achieve nearly identical weight loss through completely different biological strategies:

CagriSema (amylin + GLP-1):

• Semaglutide: GLP-1 receptor agonist — reduces appetite via hypothalamus, slows gastric emptying, improves insulin sensitivity
• Cagrilintide: Long-acting amylin analog — reduces appetite via brainstem (area postrema), provides additional satiety signaling through a separate neurological pathway

Zepbound (GIP + GLP-1):

• GLP-1 component: Same appetite reduction and metabolic effects as semaglutide
• GIP component: Glucose-dependent insulinotropic polypeptide enhances energy expenditure, improves fat metabolism, and may improve lean mass preservation

Neither mechanism is inherently "better." Amylin hits appetite from a different brain region than GLP-1. GIP hits energy expenditure and fat handling. Both strategies layer additional hormone signaling on top of GLP-1. The result is roughly the same amount of weight loss through different metabolic pathways.

This is the single biggest differentiator right now.

Zepbound: FDA-approved since November 2023. Available at pharmacies nationwide. Prescribable by any licensed provider. LillyDirect offers self-pay at $499/mo. Supply is stable.

CagriSema: Completed Phase 3 trials (REDEFINE program) with strong results. Novo Nordisk is expected to submit to the FDA in mid-2026. Under standard review timelines, the earliest possible approval would be October 2026. Realistic commercial launch: early-to-mid 2027.

The practical reality: If you start Zepbound today, you could lose 50+ lbs before CagriSema even reaches a pharmacy shelf. Weight-related health complications — sleep apnea, joint pain, diabetes risk, cardiovascular strain — don't wait for drug approvals. If you need treatment, waiting 12+ months for a drug that's 0.2% more effective is not a sound medical strategy.

CagriSema contains semaglutide — the SELECT trial molecule. The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4mg injection reduced major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease and obesity. This is the strongest cardiovascular evidence in obesity medicine.

While CagriSema itself hasn't had a dedicated cardiovascular outcomes trial, its semaglutide component provides a reasonable basis for expecting some cardioprotection. The cagrilintide (amylin) component's cardiovascular effects are less studied but show no concerning signals.

Zepbound (tirzepatide) has no completed CV outcomes trial. Lilly's SURPASS-CVOT trial is ongoing with results expected around 2027. Until then, no cardiovascular risk reduction claims can be made for tirzepatide.

For patients with established heart disease: The semaglutide platform (Wegovy, and by extension CagriSema) has evidence-based cardioprotection. Zepbound does not — yet. This may influence your doctor's recommendation if you have significant cardiovascular risk factors.

Zepbound pricing (known):

• List price: ~$1,086/mo
• LillyDirect self-pay: $499/mo (all doses)
• Manufacturer savings card: $25/mo for eligible commercially insured patients

CagriSema pricing (projected):

• Not yet announced — pricing will be set closer to launch
• As a novel combination product, expect premium pricing: likely $1,000+/mo minimum
• Novo Nordisk priced Wegovy injection at $1,349/mo — CagriSema will likely be at or above this level
• Manufacturer savings cards will almost certainly be available for commercially insured patients

The cost advantage goes to Zepbound — especially via LillyDirect at $499/mo. Self-pay patients will likely pay significantly more for CagriSema, at least at launch. Insurance coverage for CagriSema as a new product will take time to establish across plans.

Choose Zepbound now if:

• You need weight loss treatment today — don't wait
• You want a proven, FDA-approved drug with stable supply
• Cost matters — LillyDirect offers $499/mo self-pay
• You don't have significant cardiovascular disease
• You're comfortable with Lilly's ecosystem (potential step-down to Foundayo later)

Consider waiting for CagriSema if:

• You're already on semaglutide (Wegovy/Ozempic) and have plateaued
• You have cardiovascular disease and value the semaglutide CV data
• You're not in urgent need of treatment and can wait 12+ months
• Your doctor specifically recommends the semaglutide platform for your condition

The pragmatic approach: Start Zepbound (or Wegovy, or Foundayo) now. Lose weight. Improve your health. When CagriSema launches, you and your doctor can evaluate whether switching makes sense based on your progress and goals.